Healthcare >> CEO Interviews >> September 13, 2002
JOHN MCLAUGHLIN became President, Chief Executive Officer and a
member of the Board of Directors of Corgentech Inc. in January
2000. He co-founded EyeTech Pharmaceuticals, Inc., a company
focusing on treatments for eye disease, including a Phase III
product for the treatment of age-related macular degeneration, in
that same year. Prior to Corgentech, Mr. McLaughlin was President
of Tularik, Inc. With Genentech, Inc., for 11 years prior to
Tularik, Mr. McLaughlin held a number of senior management
positions, including Executive Vice President. He was responsible
for many of the commercial functions at Genentech, including
creation of its business strategy and the design, negotiation and
implementation of its revised relationship with then strategic
partner, F. Hoffmann-LaRoche Ltd. Previously, Mr. McLaughlin
represented major pharmaceutical companies as a Partner in a
Washington, DC, law firm that specializes in food and drug law.
He also served as Counsel to various subcommittees of the U.S.
House of Representatives and drafted numerous measures that
became U.S. Food and Drug Administration laws, including those
relating to orphan drugs, generic drugs and the export of
unapproved drugs. He currently serves as Chairman of the Board of
Directors of EyeTech Pharmaceuticals, Inc. He previously served
on the Board of Directors of IDEC Pharmaceuticals, Inc. Mr.
McLaughlin earned a BA from the University of Notre Dame and a JD
from the Catholic University of America. Profile
Mr. McLaughlin: Corgentech is focused on the discovery, development and
commercialization of novel therapies for the treatment
